Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Anant Madabhushi, PhD, executive director for the Emory Empathetic AI for Health Institute, discusses the potential of ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

When Mags Kirwan was first diagnosed with multiple myeloma three years ago, she made the conscious decision to “run her own ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

The median progression-free survival (PFS, the time a patient lives without their ... 2020 in combination with pomalidomide ...

Japan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.

In order to help provide answers to these questions, and to provide support to patients and their caregivers, The ...